Learn, Analyse & Invest
only with

+91

Download Orca

To access realtime data for Reliance Industries Ltd, and use advance features for tradingRegisterorLogin to Orca.

Marksans Pharma Ltd.

Marksans Pharma

₹ 0.00

0.00 (0.00)%

NSE

BSE

Healthcare

Small-cap - With a market cap of ₹76.34 Cr.

EX-Date	Purpose
31 05 2021	Final Dividend & Audited Results
15 06 2021	Issue Of Warrants
23 07 2021	Issue Of Warrants
11 08 2021	Quarterly Results
09 11 2021	Quarterly Results
10 11 2021	Quarterly Results (Revised)
11 02 2022	Quarterly Results
30 05 2022	Audited Results & Final Dividend
08 07 2022	Buy Back of Shares
13 08 2022	Quarterly Results
14 11 2022	Quarterly Results
20 01 2023	Inter alia, to consider and approve allotment of fully paid-up Equity Shares having face value of Re. 1/- each against the convertible warrants on preferential basis.
13 02 2023	Quarterly Results
30 05 2023	Final Dividend & Audited Results
11 08 2023	Quarterly Results
09 11 2023	Quarterly Results
13 02 2024	Quarterly Results
12 11 2024	Quarterly Results
11 02 2025	Quarterly Results
19 05 2025	Final Dividend & Audited Results
13 11 2025	Quarterly Results
05 02 2026	Quarterly Results

News

27-JAN-2026

Marksans Pharma incorporates wholly owned subsidiaries

Marksans Pharma (Europe) has been incorporated in Ireland for the purpose of carrying on the business of pharmaceutical products

03:51 PM

20-NOV-2025

Marksans Pharma’s arm gets UK MHRA approval for Cetirizine Dihydrochloride

Relonchem in the UK, has received Marketing Authorization for Cetirizine Dihydrochloride

04:13 PM

19-NOV-2025

Marksans Pharma’s arm gets USFDA’s final nod for Loperamide Hydrochloride tablets

Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhea

02:51 PM

17-NOV-2025

Marksans Pharma’s arm gets marketing authorization for two products

Relonchem has received marketing authorization from UK Medicines & Healthcare products Regulatory Agency

02:08 PM

10-NOV-2025

USFDA completes cGMP inspection at Marksans Pharma’s Goa facility

At the conclusion of the inspection, the USFDA issued zero from 483 observation

03:20 PM

05-NOV-2025

Marksans Pharma’s arm gets marketing authorization from UK MHRA

Relonchem has received marketing authorization for its product Exemestane 25mg film-coated tablets

10:28 AM

18-AUG-2025

Marksans Pharma’s arm receives marketing authorization from UK MHRA

Relonchem has received marketing authorization for Metformin Hydrochloride Relonchem 500 mg, 750 mg and 1000 mg Prolonged Release Tablets

02:25 PM

08-AUG-2025

Marksans Pharma’s arm gets approval from USFDA for Omeprazole Delayed-Release Tablets

Omeprazole is used to treat heartburn and certain other conditions caused by too much acid in the stomach

12:41 PM

30-JUN-2025

Marksans Pharma’s arm gets EIR from USFDA for New York facility

Current Good Manufacturing Practices inspection was conducted by the USFDA from April 16, 2025 to April 24, 2025

04:12 PM

19-JUN-2025

Marksans Pharma’s arm gets marketing authorization for Oxybutynin hydrochloride

Relonchem has received Marketing Authorization from UK Medicines & Healthcare Products Regulatory Agency

10:41 AM

30-MAY-2025

Marksans Pharma’s arm gets marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution

Relonchem has received marketing authorization from UK Medicines & Healthcare Products Regulatory Agency

10:41 AM

20-MAY-2025

Marksans Pharma reports 17% rise in Q4 consolidated net profit

The total consolidated income of the company increased by 25.75% at Rs 724.98 crore for Q4FY25

03:19 PM

19-MAY-2025

Marksans Pharma’s arm gets marketing authorization for Sennosides 7.5 mg Tablets

The company’s arm received Marketing Authorization from UK Medicines & Healthcare Products Regulatory Agency

04:09 PM

15-MAY-2025

Marksans Pharma’s arm receives marketing authorization for Gabapentin

The company has received this authorization from UK Medicines & Healthcare Products Regulatory Agency

11:00 AM

28-APR-2025

USFDA completes cGMP inspection at manufacturing facility of Marksans Pharma’s arm

On conclusion of the inspection, the Subsidiary has received 1 inspectional observation in Form 483

12:40 PM

20-MAR-2025

Marksans Pharma’s Goa facility gets Australian TGA’s nod to manufacture pharmaceutical formulations

The products will be manufactured at the facility in Goa, India and marketed & distributed in Australian markets through the company’s subsidiary

02:51 PM

19-MAR-2025

Marksans Pharma’s arm receives marketing authorization for Baclofen

Relonchem has received Marketing Authorization from UK MHRA

04:40 PM

25-FEB-2025

Marksans Pharma’s arm receives marketing authorization

Relonchem has received marketing authorization for the product Ibuprofen and Paracetamol

01:00 PM

12-FEB-2025

Marksans Pharma reports 27% rise in Q3 consolidated net profit

Total consolidated income of the company increased by 20.10% at Rs 709.70 crore for Q3FY25

11:10 AM

23-NOV-2024

Marksans Pharma gets USFDA’s final approval for Loratadine Tablets

This product is generic version of Clartin tablet in the same strength of Bayer Healthcare

02:47 PM

06-NOV-2023

Marksans Pharma’s arm receives Marketing Authorisation for product Cyanocobalamin

Relonchem has received Marketing Authorisation from UK MHRA

02:41 PM

03-NOV-2023

Marksans Pharma’s arm gets EIR from USFDA

No 483’s were issued during the Audit

11:27 AM

01-NOV-2023

German health authorities inspect Marksans Pharma’s manufacturing facility in Goa

The Authorities have not found any critical/major observations

12:29 PM

03-OCT-2023

Marksans Pharma gets USFDA’s nod for Esomeprazole Magnesium Delayed-Release Capsules

The product will be manufactured at the Company’s formulation manufacturing facility in Goa, India

02:08 PM

22-AUG-2023

Marksans Pharma gets USFDA’s final approval for Guaifenesin Extended-Release Tablets

The company expects to launch the product immediately

02:59 PM

07-AUG-2023

USFDA completes PADE inspection at Marksans Pharma’s Goa facility

The inspection closed with two observations

02:16 PM

12-JUL-2023

Marksans Pharma gets USFDA’s final approval for Acetaminophen and Ibuprofen Tablets

The company plans to launch the product immediately

11:57 AM

19-APR-2023

Marksans Pharma completes acquisition of manufacturing site from Tevapharm India

The acquired facility will enable Marksans Pharma to potentially double the existing Indian capacity from 8bn units per annum currently

12:59 PM

10-MAR-2023

Marksans Pharma gets USFDA’s final approval for Famotidine Tablets

The product is bioequivalent to the reference listed drug, Pepcid AC tablets, a registered trademark of Johnson & Johnson Consumer

12:21 PM

23-JAN-2023

Marksans Pharma’s arm gets UK MHRA approval for Fluoxetine Oral Solution

Therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders

02:27 PM

20-JAN-2023

Marksans Pharma raises Rs 372.40 crore via conversion of warrants

OrbiMed’s exercise of warrant conversion will further strengthen the Company’s net cash position to over Rs 650 crore

04:46 PM

11-OCT-2022

Marksans Pharma enters into Business Transfer Agreement with Tevapharm India

Through the acquisition, the company plans to double the existing Indian capacity from 8bn units per annum currently

03:42 PM

21-JUL-2022

Marksans Pharma gets USFDA approval for Pregabalin Capsules

Pregabalin capsules (RLD Lyrica) had estimated annual sales of $263 million in the U.S. (IQVIA MAT March 2022)

02:20 PM

21-JUN-2022

Marksans Pharma’s arm recalls Kroger Brand Aspirin and Ibuprofen bottles

Total 12 lots containing 209,430 units have been recalled

12:48 PM

10-JUN-2022

Marksans Pharma acquires entire stake in Access Healthcare

Earlier, in April 2022, the company had signed a share purchase agreement to acquire a 100% stake in Access Healthcare

02:22 PM